Corcept (CORT) Moves 6.5% Higher: Will This Strength Last?

Corcept Therapeutics (CORT) shares soared 6.5% in the last trading session to close at $42.27. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 15.7% gain over the past four weeks. The company's sole marketed drug, Korlym, approved for treating Cushing's syndrome, is witnessing strong demand and driving growth. Also, a new drug application for the lead candidate, relacorilant, to treat Cushing's syndrome is expected to be filed in ...